Biography for Eric Palmer
Eric Palmer, Senior Editor
Eric Palmer is a business and technology journalist with more than three decades of prize-winning experience as a reporter and editor with daily, weekly, monthly and online publications. He was healthcare reporter for The Kansas City Star before becoming deputy business editor for the daily newspaper. He spent eight years as editor of The Kansas City Business Journal, which had a strong emphasis on the healthcare industry. On the personal side, he is an avid fly fisherman, cooks and collects wine, and likes to travel with his family. Eric is based in Kansas City and can be reached at email@example.com.
Articles by Eric Palmer
Denmark's Xellia Pharmaceuticals has bought the former Ben Venue plant, at one time the most notorious U.S. plant under FDA supervision, a facility responsible for dozens of recalls and a slew of drug shortages.
An FDA warning letter found that for years, Dr. Reddy's Laboratories was testing drug batches in a laboratory that the FDA was never told existed and often shipped to the U.S. products that had repeatedly failed tests for impurities.
All of the market buzz may center on Pfizer's $160 billion tax inversion deal to buy Allergan, but Teva Pharmaceuticals is really getting the market love.
Novartis' blockbuster-in-waiting, Entresto, has been handed its second big approval. The new heart failure drug has snagged an OK from the European Commission.
In another striking FDA turnaround for Bristol-Myers Squibb's Opdivo, the agency has approved it for treating advanced renal cell carcinoma just a week after granting priority review.
The FDA has approved Takeda Pharmaceutical's Ninlaro, a treatment for multiple myeloma that the Japanese company hopes can get established before its blockbuster Velcade loses patent protection.
After finally turning back the long-running takeover attempt by Mylan, Perrigo assured shareholders they could expect "industry-leading future growth prospects." In its first move toward delivering on that promise, the OTC specialist said today it will buy the U.S. rights to AstraZeneca's Crohn's disease drug Entocort.
In the jockeying for share in the brand-new market for the specialized PCSK9 cholesterol-lowering meds, Amgen has picked up an edge over Sanofi by nailing a formulary exclusive with CVS. To get that preferred spot, Amgen has again agreed to tie the price of the drug to its effectiveness.
Even if Brent Saunders does not get the CEO role at Pfizer as a condition of Allergan agreeing to a buyout, which is reportedly being demanded, he will still get a huge payday from the deal. In the short time that he has been CEO of Allergan, Bloomberg figures he has collected shares and options that should allow him to cash out for nearly $190 million.
After 8 months of first cajoling and then browbeating, Horizon Pharma has given up its hostile takeover attempt to buy Depomed. It threw up its hands and walked away after a California judge stymied its effort, ruling that Horizon had improperly used confidential information in its bid.